Benzinga | Mar 26, 2021 06:24AM EDT

HC Wainwright & Co. Maintains Buy on Corvus Pharmaceuticals, Lowers Price Target to $9.5

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Corvus Pharmaceuticals (NASDAQ:CRVS) with a Buy and lowers the price target from $12 to $9.5.